Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cures Act

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

- PMLiVE

Drug pricing is pharma’s top concern in 2019

More than half of industry respondents say pricing will have the greatest negative impact this year

- PMLiVE

FDA clears Sandoz and Pear’s Opioid Use Disorder app

The app incorporates CBT to improve high relapse rates

- PMLiVE

Reference price bill tabled in US House and Senate

The new measure could reduce median drug prices by around 43%

- PMLiVE

Democrats regain control of House in mid-terms

Biotech and pharma share price indexes have climbed since the news broke

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links